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Abstract
Background: The objective of this paper is to estimate the amount of cost-savings to the
Australian health care system from implementing an evidence-based clinical protocol for diagnosing
emergency patients with suspected pulmonary embolism (PE) at the Emergency department of a
Victorian public hospital with 50,000 presentations in 2001–2002.
Methods: A cost-minimisation study used the data collected in a controlled clinical trial of a clinical
protocol for diagnosing patients with suspected PE. Thenumber and type of diagnostic tests in a
historic cohort of 185 randomly selected patients, who presented to the emergency department
with suspectedPE during an eight month period prior to the clinical trial (January 2002 -August
2002) were compared with the number and type of diagnostic tests in745 patients, who presented
to the emergency department with suspected PE from November 2002 to August 2003. Current
Medicare fees per test were usedas unit costs to calculate the mean aggregated cost of diagnostic
investigation per patient in both study groups. A t-test was used to estimate the statistical
significance of the difference in the cost of resources used for diagnosing PE in the control and in
the intervention group.
Results: The trial demonstrated that diagnosing PE using an evidence-based clinical protocol was
as effective as the existing clinical practice. The clinical protocol offers the advantage of reducing
the use of diagnostic imaging, resulting in an average cost savings of at least $59.30 per patient.
Conclusion: Extrapolating the observed cost-savings of $59.30 per patient to the wholeof
Australia could potentially result in annual savings between $3.1 million to $3.7 million.
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In 1995 the National Health and Medical Research Coun-
cil announced its commitment to developing evidence-
based clinical practice guidelines "to promote best prac-
tice linked to outcomes and effective cost management".
However, the uptake of evidence-based clinical practices
has not been free of problems [1]. Evidence-based medi-
cine is typically promoted on the basis of superior clinical
outcomes while the costs of changing to it, borne by indi-
vidual organizations and practitioners, are downplayed in
favour of population benefits [2]. Although there is a
growing number of publications emphasising the impor-
tance of conducting evaluations of clinical guidelines for
diagnosis and prophylaxis of pulmonary embolism and
deep vein thrombosis [3], evaluations are either confined
to clinical outcomes [4-6] or based on the secondary use
of data from the literature rather than on prospective data
collection [7,8]. This study is an economic evaluation of a
clinical protocol for diagnosing patients with suspected
PE based on the data collected in the course of a clinical
controlled trial. The purpose of the study is to demon-
strate how individual hospitals can achieve an effective
cost management through introduction of the best prac-
tice for diagnosing emergency patients with suspected
pulmonary embolism (PE).
Venous thromboembolic disease, which includes PE and
deep venous thrombosis, is the third most common acute
cardiovascular disease, exceeded only by cardiac ischemia
and stroke. In the United States, the incidence of PE has
been estimated to be approximately 1/1000 persons per
year [9] and 17 – 26% of untreated patients with PE may
die [10,11]. PE – related mortality can be dramatically
reduced with anticoagulation therapy [12]. However,
because making or excluding the diagnosis of PE based
upon clinical evaluation alone is unreliable [13], diagnos-
tic imaging testing of some type is used for this purpose.
Diagnostic imaging of the deep veins of the lower limbs or
the pulmonary arterial circulation, either with ventilation
perfusion (VQ) lung scanning, Doppler ultrasound (US)
of the lower limb veins, digital subtraction angiography
(DSA) or, more recently, computed tomographic pulmo-
nary angiography (CTPA) have been used to diagnose PE.
Unfortunately, the most commonly used tests, VQ and
CTPA, have substantial rates of false negative and indeter-
minate results [14-16]. This leads either to increasingly
expensive and invasive investigations that, with the excep-
tion of US, also involve ionising radiation or anticoagula-
tion therapythat may be unnecessary.
In recent years, it has been recognized that measurement
of the degradationproducts of fibrin (D-dimer) circulating
in plasma can be useful in ruling out PE if the levels of D-
dimer are low and the pre – test likelihood of PEis low. D-
dimer assay is a relatively inexpensive test, which is per-
formed on a small sample of venous blood drawn from
the patient. The number of such assays available on the
market has rapidly increased, and the sensitivityof the var-
ious assays ranges from 80% – 100%. The variability in
sensitivity of the assays has probably been responsible for
the lack of widespread clinical uptake of D-dimer as a way
of excluding PE. When a less sensitive assay yields a nega-
tive result in a patient at high risk of VTE, the post test
probability of PE may be too high to allow anticoagula-
tion to be withheld [17-19].
However, combination of standardized clinical risk
assessment with D-dimer has the potential to be a power-
ful and non-invasive way of excluding PE which is associ-
ated with a high negative predictive value for PE. The two
major published strategies for ruling out PE based on the
combination of clinical risk assessment and negative D-
dimer were developed by Wells et al[18] and Kline et al
[19] and more recently Kline and Wells [20].
Wells' strategy has been independently validated [17] and
was shown to havea few disadvantages such as classifying
a majority of patients as being at intermediate risk of PE,
which mandated further investigation with imaging. In
addition, the Wells protocol involved a degree of subjec-
tive judgement of the likelihood of PE relative to other
diagnoses, which is associated with an elevated inter-
observer variation in the level of risk assigned to patients.
The strategy suggested by Kline et al [19] had not been
prospectively tested until recently [21]. However, its sim-
plicity and relative lack of subjectivity make it attractive
for use in an environment, such as the emergency depart-
ment of a teaching hospital, where the level of clinical
experience and training is variable.
In 2002–2003, the Department of Diagnostic Imaging in
cooperation with the Emergency and Haematology
Departments of Monash Medical Centre, a Victorian720
bed teaching hospital with 50,000 annual emergency
presentations, conducted a trial of a clinical protocol for
diagnosing patients with suspected PE based on the strat-
egy suggested by Kline et al [19], which is explained
below.
In the 12 months prior to the clinical trial more than
1,000 patients were assessed for suspected PE in the Emer-
gency Department. The likelihood of PEwas first esti-
mated on the basis of medical history and physical
examination and a D-dimer assay was ordered in about
50% of the cases (see Figure 1 below). However, the sen-
sitivity of the test was not seen as high enough towithhold
treatment, and subsequent to a negative outcome of D-
dimer, an imaging test (typically a VQ) was also
requested. The results of VQ can be indeterminate in up toPage 2 of 10
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independently of any pre-test clinical assessment added to
the high rate of requests for diagnostic imaging and
increased the cost of assessment.
Implementation of a protocol for the risk assessment of
PE, which combines the standardized clinical risk assess-
ment with D-dimer, has resulted in thereduced use of
diagnostic imaging tests without any additional risk of
misdiagnosing PE. Clinical risk of the protocol was
assessed by calculatingthe negative predictive value of PE
in the patients with both "low risk" and a negative D-
dimer result.
The objective of this paper is to use the data of the clinical
trial to estimate the amount of cost-savings to the Austral-
ian health care system ofan evidence-based clinical proto-
col for diagnosing emergency patients with suspected
pulmonary embolism (PE). The detailed description of
the original clinical trial can be found elsewhere [21].
Methods
Study groups
The intervention group consisted of 745 patients with 789
presentations to the emergency department with sus-
pected PE between November 2002 and August 2003.
Historical controls were selected randomly from a group
of patients investigated for PE in the emergency depart-
ment (ED) in the 8 months (January 2002 -August 2002)
preceding the study and this group consisted of 185
patients with 190 attendances.
All patients aged 18 or over who attended the ED during
the study period and who were thought to have possible
PE were potential study subjects. This included patients
who had either a D-dimer, VQ, CTPA, or lower limb
Assessment and diagnosis procedures in the control group* See the attached file Figure 1 and Figure 2Figure 1
Assessment and diagnosis procedures in the control group* See the attached file Figure 1 and Figure 2. *Use of 
diagnostic tests (%) is calculated with respect to the number of attendances **Categorisation into the low or high risk group 
(i.e. completing an assessment according to the protocol) is defined as answeringall six questions concerning physiological 
parameters and medical history that are recorded on the specially designed assessment card, which also contained a request 
form for imaging or D – dimer, if applicable according to the rules of the structured decision tool [19]. The protocol-specific 
assessment did not occur for any of the control subjects and thus the risk profile for the control population is unknown.
Assessed for the likelihood 
of PE (100%) 
D-dimer  
(54%) 
 No D-dimer  
(46%) 
VQ/US/CTPA/DSA 
(77%) 
Categorised into high or 
low risk group**  
(0%)
Control group 
N = 185 
(190 attendances) Page 3 of 10
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rather than deep venous thrombosis alone. This was
established on the basis of clinical notes written on the
pathology and/or imaging request forms, or if these were
notsufficient, study coordinators investigated patients'
medical records. The principal investigator (SG) read 5%
of medical records for included and excluded patients and
there was 92% agreement between the principal investiga-
tor and the study coordinators about the outcomes.
Patients who were taking anticoagulant medication on
presentation to the EDor who were found to have received
it during the follow up period for reasons other than diag-
nosed PE or DVT were excluded from the final analysis of
the negative predictive value of the combination of low
risk and negative D-dimer. This is because these patients
had a reason other than the effectiveness of the diagnostic
strategy for not developing PE during the 3 months follow
up. They were not, however, excluded from initial inclu-
sion in the study group. Pregnancy was not an exclusion
criterion nor were previous DVT or PE.
The sample size of the intervention group was calculated
to estimate the negative predictive value (NPV) of PE in
the "low risk" and negative D-dimer group of patients
with 5% precision. We assumed an expected NPV of100%
based on 99% observed by Kline et al [19]. After allowing
for 20% of loss to follow up and for 15% anticoagulation
rate during follow up the required sample size was esti-
mated at 135 patients. Recruitment continued until this
number was achieved.
For the comparison between control and study subjects
with respect to the proportion of patients who received
imaging for PE, it was calculated that 184 control subjects
would be needed in order to detect, with 90% power ata
5% level of significance, a 15% reduction in the use of
diagnostic imaging from a base of 80%.
Intervention
The patients were assigned into either a "low risk" or a
"high risk" PE category according to the outcomes of the
standardised clinical assessment, using the protocol
designed by Kline et al [19]. The clinical protocol devel-
oped by Kline et al (2002) is a decision tool based on a
combination of
a) Measurement of physiological parameters (heart rate,
blood pressure, arterial oxygen saturation, calf diameter)
and medical history (e.g. pre-existing lung disease, hae-
moptysis, history of general anaesthesia in the preceding
month)
b) D-dimer assay result
Compared to other strategies it has clear and simple deci-
sion-making rules, a high level of inter-rater reliability
(90%) and a 99% NPV for PE (for the combination of low
clinical risk and negative D-dimer).
Clinicians working in the Emergency Department were
trained to perform riskassessments using a decision tool
suggested by Kline et al [19] for all patients whom they
suspected may have PE and to document the result (high
or low risk) on a form designed for the trial. The form con-
tained the six questions comprising the decision tool and
an imaging request to be filled if the conditions of the pro-
tocol were met. During the study period, completion of
the form was required before imaging would be provided
for EDpatients with suspected PE.
Patients categorized as "low risk" were to have a D – dimer
assay as the first diagnostic test. The clinicians were
instructed not to request pulmonary vascular imaging
(VQ, CTPA, lower limb venous ultrasound, or DSA)if the
result of the assay for the "low risk" group was negative, as
these patients were at extremely low risk of PE. Only those
patients from the "low risk" group for whom a D-dimer
assay proved positive were to proceedto further diagnostic
imaging, starting with a VQ scan. Patients assigned to the
"high risk" group did not require a D-dimer assay accord-
ing to the protocol, but were supposed to receive imaging,
with a VQ scan as the firstdiagnostic test.
Figure 1 and Figure 2 describe the assessment and diag-
nostic procedures forthe suspected pulmonary embolism
in the control and study groups respectively.
Resource use was first estimated in natural units (the
number of diagnostictests by test category ordered in the
control and intervention groups). Themonetary value of
the resources was obtained by using the Medicare Benefit
Schedule fees as unit costs (Table 1).
Time spent by staff in preparing the clinical protocol
incorporating the decision tool [19] for assessing patients
with suspected PE as well as timespent by clinical staff on
attending training sessions adds to the cost of interven-
tion. Information on the number of hours spent in prep-
Table 1: Diagnostic test unit costs from MBS fee.
Code Diagnostic Test 85% of 
MBS fee
100% of 
MBS fee
65120 D-dimer $11.65 $13.65
61348 Ventilation perfusion (VQ) lung scan $335.55 $386.45
55244 Doppler Ultrasound (US) $144.05 $169.45
57350 Computerised tomography (CTPA) $461.20 $512.10Page 4 of 10
(page number not for citation purposes)
Cost Effectiveness and Resource Allocation 2006, 4:12 http://www.resource-allocation.com/content/4/1/12
Page 5 of 10
(page number not for citation purposes)
Decision tool for high risk and low risk assessment groups* See the attached file Figure 1 and Figure 2Figure 2
Decision tool for high risk and low risk assessment groups*. See the attached file Figure 1 and Figure 2. * Use of 
diagnostic tests (%) is calculated with respect to the number of attendances **Risk assessment in 35% of the patients presented 
with suspected PE may or may not have occurred but did not involve completion of risk assessment cards containing the struc-
tured decision tool. With respect to these patients it is uncertain whether the use of diagnostic resources has been influenced 
by the rules outlined in the protocol. ***During the intervention period an assessment involving a structured decision tool was 
performed on 513 (65%) of attendances although a valid assessmentof low or high risk was only attained for 491 (62%) attend-
ances due to the incomplete answers to six questions concerning physiological parameters andmedical history that are 
recorded on the specially designed assessment card. This resulted in the uncertain outcome of the assessment for 22 (2%) 
attendances.
Negative 
(19%) 
No treatment 
Positive 
(26%) 
VQ/US/ 
CTPA/DSA
(56%) 
D-dimer 
(45%) 
Negative 
No treatment 
Intervention Group 
N = 745 
(789 attendances) 
Categorised into high or 
low risk group (65%) 
No documentation of risk 
assessment for the likelihood 
of PE ** (35%) 
Positive 
Treat for PE 
Low risk  
(47%) 
Uncertain***  
(2%) 
High risk  
(16%) 
Cost Effectiveness and Resource Allocation 2006, 4:12 http://www.resource-allocation.com/content/4/1/12aration and conducting training sessions as well as
information on the number and clinical staff category of
the attendees was collected. The average hourly rates by
staff category were used to estimate the monetary value of
time spent on implementation of the clinical protocol.
Follow up
All patients who were assessed as being "low risk" and
who also had a negative on D-dimer assay result were fol-
lowed up for the three months following their ED attend-
ance to establish if they had been investigated for or
diagnosed with DVT or PE during this period of time.
They were also asked whether they had received anticoag-
ulation during follow up. The hospital database was also
checked to determine if they had re-presented during the
follow up period with PE or DVT. Patients were consid-
ered lost to follow up after three mailings of the follow up
questionnaire and five phone calls(which occurred during
the day and evening both during the week and on week-
ends) failed to make contact. Patients who were lost to fol-
low up had their names submitted to the Victorian
Registry of Births, Deaths, and Marriages to determine if
they had died in Victoria during the follow up period. It
was decided prior to commencement of the study that any
deaths which occurred during the follow up period would
be assumed to be due to pulmonary embolism unless this
possibility could be excluded by post mortem examina-
tion.
Clinical outcome
The combination of low clinical risk and negative D-
dimer result wasobserved in 150 attendances by 148 study
subjects. Of the 150 attendances, 130 attendances had fol-
low up completed successfully, resulting in a loss to fol-
low up of 13%. Of the 130 subjects successfully followed,
16 received an anticoagulant medication either at the time
of their presentation to the ED with suspected PE or at
some time during the follow up period. The reason for
receiving anticoagulation medication were either previ-
ously (prior to the ED presentation) diagnosed throm-
boembolic disease (e.g. pulmonary embolism) or
pulmonary or cerebral thromboembolic complications in
patientswho were predisposed to them due to severe car-
diac failure or coagulation disorders. No patient with low
risk and negative D dimer was commenced on anticoagu-
lants during the follow up period due to diagnosed PE or
DVT. Thus, 114 patients satisfied all inclusion and exclu-
sion criteria for evaluation of the accuracy of the combina-
tion of the clinical risk assessment and negative D –
dimer.
Of these 114 patients with negative D dimer and no anti-
coagulation, 1 patient (1%) had PE. He was a 43 year old
male with a history of cardiac arrhythmias and intermit-
tent medical treatment for the arrhythmias. He had a VQ
performed based on the clinical judgement of the attend-
ing ED physician, despite being classified as low risk for
PE and having a negative D – dimer result and the scan
was interpreted as high probability for PE.
Thus the negative predictive value (NPV) of the combina-
tion of low risk andnegative D – dimer in our study group
was 99% (95% CI = 96% – 100%).
None of the 20 patients lost to follow up were investigated
or diagnosed with PE at the hospital (or at the geographi-
cally closest public hospital, which was also part of the
hospital network) during the 3 month follow up period.
An audit of the Victorian Registry of Births, Deaths, and
Marriagesrevealed that none of these patients were
recorded as having died in the State of Victoria during the
follow-up period.
This result confirmed the existing clinical evidence that
the risk management strategy of the protocol adopted for
the trial excludes almost all cases of clinically significant
PE without the need for pulmonary vascular imaging
[19,23]. The trial protocol did not introduce any addi-
tional clinical risk in comparison with existing practices
for diagnosing PE, while it had the advantage of reduced
utilisation of expensive diagnostic imaging resources.
Economic evaluation
The study hypothesis was that upon introduction of an
evidence-based protocol there would be no difference in
the number of correctly diagnosed PE patients, but that
there would be a saving in the use of resources primarily
from a reduction in the number of pulmonary vascular
imaging tests for patients categorised into a "low risk"
group who also had negative D-dimer at the pre-test
assessment. In addition, it was expected that there might
be a small savings from patients in the "high risk" group
by avoiding a D-dimer test.
The objective of the economic evaluation was to estimate
the cost-savings resulting from implementation of the evi-
dence-based clinical protocol by comparing the average
monetary value of resources used for diagnosis of sus-
pected PE in the control group with the corresponding
monetary value of resources used in the intervention
group. Economic evaluation was conducted from the per-
spective of the Australian health care system.
Cost of resource use
Resource utilisation by category of diagnostic tests for
both groups was collected during the clinical trial. Current
Medicare Benefit Schedule (MBS) fees for a D-Dimer
assay, a VQ scan, a US and a CTPA, were used as unit costs
[24]. The Department of Diagnostic Imaging routinely
performs these tests for the outpatient group and hasPage 6 of 10
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ule fees) adequately reflect the hospital's expenditures.
This is probably a conservative estimate of unit costs, so
wehave conducted our analysis using both 85% and
100% of MBS fees. These are presented in Table 1. All
resource use was aggregated by the category of diagnostic
test and valued at current MBS fee per test to create total
costs of diagnostic investigation for the control and the
intervention groups.
The difference in the total cost of diagnostic tests per
patient in the control and intervention groups produced
an estimate of the amount of cost-savings due to imple-
mentation of the evidence-based protocol.
Results
Table 2 shows demographic characteristics of the patients
in the control and intervention groups.
No statistically significant differences were found between
the control andintervention groups with respect to mean
age (p = 0.30), gender (Pearson Chi – square = 0.33; df =
1; p = 0.62) or positive diagnosis of PE on imaging (Chi-
square = 1.1, df = 1; p = 0.29) as a proxy for the prevalence
of PE in the study groups. True prevalence of PE in the two
groups is unknown as, according to the trial protocol,
only the "low risk" patients who were D-dimer negative
were followed up to determine if they developed PE dur-
ing the 3 month period after their initial investigation.
During the trial, risk assessment as outlined in the proto-
col was performedand documented for 513 (65%) of the
attendances, if judged by the number of completed risk
assessment cards that were returned to the study coordina-
tors. However, there was anecdotal evidence that the
adherence to the protocol was in fact higher, but during
periods of high demand the emergency department med-
ical staff did not complete risk assessment cards.
Outcome of the clinical trial confirmed that the evidence-
based protocol for diagnosing PE is just as effective (in
terms of NPV) as the clinical practice it has replaced. In
such instances where the alternative clinical practice is not
associated with improved outcomes but is suggestive of
reduced utilisation of limited health care resources, such
as diagnostic imaging, a cost-minimisation analysis is
employed.
Table 3 shows the difference in proportion of diagnostic
tests performed inthe control and intervention groups.
Digital subtraction angiography was ordered only once in
the control group and was excluded from the calculations
since this invasive test, which was occasionally used to
confirm or exclude PE in patients with high risk and oth-
erwise indeterminate imaging results, has been practically
replaced by anon-invasive CT pulmonary angiography
(CTPA).
After introducing an evidence-based protocol, the propor-
tion of patients who received diagnostic imaging tests
reduced across all categories of tests, although the differ-
ence was statistically significant only with respect to VQ
scans. As expected, utilisation of D-dimer increased signif-
icantly in the intervention group. Table 3 shows that
93.2% of the intervention group patients had a D-dimer
test. The majority of patients from the interventiongroup
were assigned a D-dimer assay regardless of the outcome
of the pre-test assessment, and the expected reduction in
the number of D-dimer assays in the "high risk" group
was not observed. Although doctors continued perform-
ing D-dimer on some patients from the "high risk" group,
Table 2: Demographic characteristics of patients in the control and intervention groups.
Control n = 185 Intervention n = 745
Age 56.2 (SD 18.4) 55.0 (SD 19.1)
Gender (% male) 40.5 42.9
Positive diagnosis of PE on imaging* (%) 12.0 9.5
SD = standard deviation
*positive diagnosis of PE on imaging is derived from high probability VQ or positive CTPA or positive lower limb venous ultrasound.
Table 3: Difference in the proportion of diagnostic tests performed in the control and intervention groups.
Control n = 185 Intervention n = 745 Absolute risk difference Pearson Chi-Square Statistics (df = 1) P-value
D-dimer 54.1% 93.2% 48.9% 181.5 <0.0001
VQ 70.3% 52.9% -17.4% 18.2 <0.0001
LLUS 20.5% 17.6% -2.9% 0.87 0.4
CTPA 9.2% 8.1% -1.1% 0.25 0.6Page 7 of 10
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formed, appropriately, on "low risk" patients.
Implementation of the evidence-based protocol in the
emergency department involved 10–12 hours of prepar-
ing educational material and 8–10 one hour small group
teaching sessions which involved 15 medical and nursing
staff from the emergency department, and eight staff from
the Diagnostic Imaging Department, including medical
imaging technologists, radiologists and radiology resi-
dents at all levels of clinical experience. These sessions
consisted of a presentation of the theory surrounding the
principle of exclusion of PE using D-dimer, discussion of
the problems with imaging tests performed on patients
with PE (in particular, indeterminate results) and a
detailed discussion of what was required to perform the
risk assessment.
Assuming that the hourly rate of the members of the pro-
tocol implementation team is $60, the cost of preparing
educational material and conducting training sessions is
about $1,200. The opportunity cost for the medical and
diagnostic imaging staff to attend the sessions is estimated
at about $1,800 assuming that the average hourly rate for
23 staff members who attended the training sessions is
$80.
Table 4 shows the average costs per patient in the control
and interventiongroups using 85% of MBS fees as a lower
estimate.
Applying 85% of MBS fees as unit costs (Table 1), the esti-
mated additionalcost of protocol implementation associ-
ated with an increased use of D-dimerassays is $4.60 per
patient. However, this cost increase was more than offset
by the decreased costs of diagnostic imaging in the inter-
vention group, with the largest reduction in the cost of VQ
lung scan of $58.30 per patient. After adjusting for the
one-off costs of implementation the protocol, the total
cost of diagnostic investigation per patient from the inter-
vention group was $59.30 less than the cost per patient
from the control group. The difference was statistically sig-
nificant (t = 3.1; df = 928; p = 0.002). Applying 100% of
MBS fees as unit costs (Table 1), the estimatedreduction in
the total cost of diagnostic investigation per patient was
$68.70.
The number of presentations with suspected PE to the
emergency department of the study hospital is estimated
at 1000 patients per year. This suggests an annual cost sav-
ings of $59,300 using 85% of MBS fees ($68,700 if 100%
of MBS fees are used).
Discussion
The study found significant cost-savings to the health care
system from a reduction in the number of pulmonary vas-
cular imaging tests for patients categorised into a "low
risk" group at the pre-test assessment. At the same time the
number of D-dimer tests was greater in the intervention
groupthan in the control group. Much of this increase was
appropriate and in line with the implementation of the
evidence-based protocol, as the majority of D-dimer
assays were performed on the "low risk" patients. This
additional cost has been more than offset by the reduction
in the number and cost of diagnostic imaging investiga-
tions. Special emphasis during the training sessions
regarding the inappropriateness of D-dimer testing in
"high risk" individuals may bring additional cost-savings
in this area. However, timepressure and financial penal-
ties tied to length – of – stay in the emergency department
meant that D dimer was often performed before the doc-
tor managing the patient had time to undertake the risk
assessment as the D – dimer result was not available for 1–
2 hours after the blood speciment was drawn. This repre-
sents an organizational barrier to performing the risk
assessmentstrategy prior to diagnostic testing.
Table 4: Average costs of diagnostic tests in the control and intervention groups using 85% of MBS fees ($/per patient).
Control n = 185 (95%CI) Intervention n = 745 (95%CI) Mean cost reduction
Clinical costs
D-dimer 6.30 (5.50–7.10) 10.90 (10.60–11.10) -4.60
VQ 235.80 (213.50–258.10) 177.50 (165.40–189.50) 58.30
LLUS 29.60 (21.10–38.10) 25.30 (21.40–29.30) 4.30
CTPA 42.40 (23.00–61.80) 37.10 (28.10–46.20) 5.30
Protocol implementation cost
Preparing protocol materials and conducting training sessions 0 1.60 -1.60
Attending training sessions 0 2.40 -2.40
Total 314.10 (283.00–345.10) 246.80 (228.60–265.00) 59.30Page 8 of 10
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an increased time of risk assessment in the intervention
group. However, although no formalcategorisation of the
control subjects into "high" and "low" risk grouptook
place prior to the protocol implementation, the informal
risk assessment of the control subjects with suspected PE
was carried out by theED staff. This involved the use of the
ED resources in terms of clinicians'time spent on obtain-
ing medical history, conducting physical examination,
writing pathology request, interpreting the test outcome
etc. The decision rule introduced in the protocol is associ-
ated with one essential difference- that ordering and inter-
preting of the outcome of a D-dimer diagnostic test is no
longer occurs independently of any structured pre-test
clinical assessment.
Therefore it can be argued that no significant opportunity
cost was lost as a result of protocol implementation, how-
ever there is a possibility of a small marginal cost associ-
ated with time spent on recording the answers to 6
questions of the structured decision tool on the specially
designed. This extra time of about 2–5 minutes is believed
to be too small to significantly change the outcome of the
study. In addition, it is also possible, although there is no
way of proving this on the basis of collected data, that the
decision rule may have reduced the time involved in
patient assessment by focussing the emergency medical
staff on a few clinical findings which were the most
important in determining pre-test risk.
The use of a non-random historic control group is a limi-
tation of the study. However it was not feasible to have
within a single department two concurrent groups of
medical practitioners randomised to different training
programs or to assign patients to staff with different train-
ing. Nevertheless, there was not a significant gap in time
between the study groups and they appear to be compara-
ble in terms of risk of PE. The exact risk profile of PE in the
control group is unknown, as the risk assessment accord-
ing to the decision tool was not performed on them. It is
probably reasonable to assume, however, that it was sim-
ilar to that of the intervention group given the similar
demographic profiles of the two groups.
The implemented risk assessment strategy has gained a
high degree of acceptance by the ED medical staff of the
trial hospital and is now used as the first line "test" to
determine the requirement for imaging. This has reduced
the demand for imaging of patients with suspected PE to
a significant degree. More specific D-dimer assays, which
may become available in future, would allow even further
reduction in the need for imaging as there would be fewer
patients with false positive D-dimer results who required
imaging to rule out PE.
The study site is reasonably representative of large emer-
gency departments in Australia and there is no reason to
believe that these results could not be replicated in other
sites. If they were, there is the potential for substantial cost
savings with no increase in risk. In the absence of national
or state-wide data on the number of patients presenting to
an ED with PE we have estimated the annual national sav-
ings on the assumption that the trial hospital is represent-
ative of public hospitals with an ED. With 50,000
presentations in the trial hospital [25] the annual total
cost savings for 1000 patients with suspected PE was
about $60,000. Total Victorian presentations to ED were
705,000 [25]. The projected savings for Victoria are calcu-
lated as 705,000/50,000 × $60,000. The Victorian public
hospital system represents some 27% of public hospital
separations in Australia, suggesting a potential national
annual cost savings from the introduction of a clinical
protocol for diagnosing emergency patients with sus-
pected PE of between $3.1 million and $3.7 million
depending on which unit cost of the diagnostic tests is
used.
Conclusion
It is possible to implement a combination of bedside clin-
ical risk assessment and D-dimer assay in low risk emer-
gency department patients to exclude pulmonary
embolism. The result is a reduction in the use of imaging
with significant cost savings with no increase in health
risks for these patients.
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